Krill Excretion Boosts Microbial Activity in the Southern Ocean

Antarctic krill are known to release large amounts of inorganic and organic nutrients to the water column. Here we test the role of krill excretion of dissolved products in stimulating heterotrophic bacteria on the basis of three experiments where ammonium and organic excretory products released by krill were added to bacterial assemblages, free of grazers. Our results demonstrate that the addition of krill excretion products (but not of ammonium alone), at levels expected in krill swarms, greatly stimulates bacteria resulting in an order-of-magnitude increase in growth and production. Furthermore, they suggest that bacterial growth rate in the Southern Ocean is suppressed well below their potential by resource limitation. Enhanced bacterial activity in the presence of krill, which are major sources of DOC in the Southern Ocean, would further increase recycling processes associated with krill activity, resulting in highly efficient krill-bacterial recycling that should be conducive to stimulating periods of high primary productivity in the Southern Ocean.This research is a contribution to projects ICEPOS (REN2002-04165-CO3-O2) and ATOS (POL2006-00550/CTM), funded by the Spanish Ministry of Science and Innovation

Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy

Background: The phase IIIb, randomized, parallel-group, placebo-controlled ANDHI double-blind (DB) study extended understanding of the efficacy of benralizumab for patients with severe eosinophilic asthma. Patients from ANDHI DB could join the 56-week ANDHI in Practice (IP) single-arm, open-label extension substudy. Objective: Assess potential for standard-of-care background medication reductions while maintaining asthma control with benralizumab. Methods: Following ANDHI DB completion, eligible adults were enrolled in ANDHI IP. After an 8-week run-in with benralizumab, there were 5 visits to potentially reduce background asthma medications for patients achieving and maintaining protocol-defined asthma control with benralizumab. Main outcome measures for non-oral corticosteroid (OCS)-dependent patients were the proportions with at least 1 background medication reduction (ie, lower inhaled corticosteroid dose, background medication discontinuation) and the number of adapted Global Initiative for Asthma (GINA) step reductions at end of treatment (EOT). Main outcomes for OCS-dependent patients were reductions in daily OCS dosage and proportion achieving OCS dosage of 5 mg or lower at EOT. Results: For non-OCS-dependent patients, 53.3% (n = 208 of 390) achieved at least 1 background medication reduction, increasing to 72.6% (n = 130 of 179) for patients who maintained protocol-defined asthma control at EOT. A total of 41.9% (n = 163 of 389) achieved at least 1 adapted GINA step reduction, increasing to 61.8% (n = 110 of 178) for patients with protocol-defined EOT asthma control. At ANDHI IP baseline, OCS dosages were 5 mg or lower for 40.4% (n = 40 of 99) of OCS-dependent patients. Of OCS-dependent patients, 50.5% (n = 50 of 99) eliminated OCS and 74.7% (n = 74 of 99) achieved dosages of 5 mg or lower at EOT. Conclusions: These findings demonstrate benralizumab's ability to improve asthma control, thereby allowing background medication reduction

Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy

peer reviewedBackground: The phase IIIb, randomized, parallel-group, placebo-controlled ANDHI double-blind (DB) study extended understanding of the efficacy of benralizumab for patients with severe eosinophilic asthma. Patients from ANDHI DB could join the 56-week ANDHI in Practice (IP) single-arm, open-label extension substudy. Objective: Assess potential for standard-of-care background medication reductions while maintaining asthma control with benralizumab. Methods: Following ANDHI DB completion, eligible adults were enrolled in ANDHI IP. After an 8-week run-in with benralizumab, there were 5 visits to potentially reduce background asthma medications for patients achieving and maintaining protocol-defined asthma control with benralizumab. Main outcome measures for non–oral corticosteroid (OCS)-dependent patients were the proportions with at least 1 background medication reduction (ie, lower inhaled corticosteroid dose, background medication discontinuation) and the number of adapted Global Initiative for Asthma (GINA) step reductions at end of treatment (EOT). Main outcomes for OCS-dependent patients were reductions in daily OCS dosage and proportion achieving OCS dosage of 5 mg or lower at EOT. Results: For non–OCS-dependent patients, 53.3% (n = 208 of 390) achieved at least 1 background medication reduction, increasing to 72.6% (n = 130 of 179) for patients who maintained protocol-defined asthma control at EOT. A total of 41.9% (n = 163 of 389) achieved at least 1 adapted GINA step reduction, increasing to 61.8% (n = 110 of 178) for patients with protocol-defined EOT asthma control. At ANDHI IP baseline, OCS dosages were 5 mg or lower for 40.4% (n = 40 of 99) of OCS-dependent patients. Of OCS-dependent patients, 50.5% (n = 50 of 99) eliminated OCS and 74.7% (n = 74 of 99) achieved dosages of 5 mg or lower at EOT. Conclusions: These findings demonstrate benralizumab's ability to improve asthma control, thereby allowing background medication reduction. © 202

Time series of vertical flux of zooplankton fecal pellets on the continental shelf of the western Antarctic Peninsula

Zooplankton fecal pellet contribution to particulate organic carbon (POC) flux over the continental shelf of the western Antarctic Peninsula (WAP) was investigated to better understand the possible effects of changes in zooplankton community structure, due to climate change, on carbon export. Fecal pellets were collected at 170 m depth in a moored sediment trap from January 2004 to January 2009. Fecal pellet shape and size (i.e., carbon content) were quantified to assess flux of pellets from different zooplankton taxa and compared between seasons and years. Fecal pellet POC constituted the dominant proportion of total POC flux, with summer (November to April) pellet POC flux (67%) significantly higher than winter (May to October) pellet POC flux (34%), while phytodetritus or fecal \u27fluff\u27 constituted the remainder. Cylindrical euphausiid pellets contributed to a monthly mean of 72% of total fecal pellet flux; ovoid copepod and tabular salp pellets contributed significantly less (22 and 6%, respectively). Cylindrical and ovoid pellet export was significantly higher in summer, while 48% of tabular pellet flux occurred in winter. Tabular pellets had the highest carbon content (median = 1.03 mu gC pellet(-1), highest 134.9 mu gC pellet(-1)), followed by cylindrical (0.20 mu gC pellet(-1)) and ovoid (0.04 mu gC pellet(-1)) pellets. As krill fecal pellets are the dominant component of particle export in the WAP, we hypothesize that a decrease in krill and increase in salps in the region could alter the export of POC to the deep sea

Alpha-1-Antitrypsin-Mangel (AATM) – Ein Expertenstatement

Dieses Statement wurde erstellt, um einen Überblick über Diagnostik und Therapie des Alpha-1-Antitrypsin-Mangels (AATM) zu erstellen. Die Erstellung des Dokuments wurde durch die Deutsche Gesellschaft für Pneumologie und die Deutsche Atemwegsliga initiiert. Es spiegelt die aktuelle Datenlage wider und bezieht sich auf die vorliegenden Leitlinien und Statements der internationalen und nationalen Fachgesellschaften. An der Erstellung sind deutsche, schweizerische und österreichische Alpha-1-Centren beteiligt